Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults
Balfaxar demonstrated effective hemostasis in 94.6% of patients versus 93.5% of patients for Kcentra. International Normalised Ratio (INR)
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent
BALFAXAR was found to be clinically non-inferior to Kcentra, resulting in early study termination at the prespecified interim analysis.1,2. Percentage of
Balfaxar met the primary endpoint of hemostatic efficacy and was determined to be non-inferior to Kcentra, with Balfaxar demonstrating effective
Balfaxar was non-inferior to Kcentra. Balfaxar demonstrated effective hemostasis in 94.6% of patients versus 93.5% of patients for Kcentra.
between treatment arms: 81.9% for BALFAXAR vs. 77.7% for Kcentra. Most commonly reported TEAEs by preferred term ( 5% in either group
Clinical study for Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in
Balfaxar, Kcentra, Beriplex P/N [Canadian product]: IV: Administer at room Prothrombin complex concentrate vs. fresh frozen plasma in adult
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are